Saturday 17 October 2026 Export BLRX’s income statement to Excel — free account

BioLineRx Ltd.

BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024. In the quarter to June 2026, revenue fell 3.29%, EPS grew 23.0%, free cash flow fell 1,827.7% and total debt fell 40.2%, each against the same quarter a year earlier.

2.04 0.01 −0.49%

Follow BLRX

Alert me

Market cap: $10.2M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 4/9
Altman Z: −13.80
Beneish M: −1.01
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 10.21

Revenue 1.39

Net Income (10.14)

Free Cash Flow (10.81)

Net Debt (6.38)

Current Ratio 1.20

Debt/Equity 0.40

P/E ratio 0.00

Fwd P/E (0.45)

P/S ratio 6.51

P/B ratio 0.55

Past 5Y EPS Growth —

This Y EPS Growth 94.33%

Next Y EPS Growth 19.75%

Next Y revenue growth 37.29%

Next 5Y EPS Growth 57.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 6.27%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	43	20	21	13
Receivables	1	4	0	1
Inventory	2	3	2	2
Other	—	—	—	—
	47	27	24	16

	2023	2024	2025	Q'26
Payables	14	9	5	7
ST’ Debt	3	4	4	4
Other	25	2	2	2
	43	15	12	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(6.88%)	1.17%	(22.85%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	7	5	5	12	29

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(3)	0	(2)	(3)	(8)
’24	(14)	(11)	(10)	(9)	(44)
’23	(8)	(10)	(10)	5	(23)
’22	(6)	(6)	(9)	(6)	(26)
’21	(6)	(7)	(5)	(6)	(24)
’20	(7)	(6)	(5)	(5)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(3)	0	(2)	(3)	(8)
’24	(14)	(11)	(10)	(9)	(44)
’23	(8)	(10)	(10)	5	(23)
’22	(6)	(6)	(9)	(6)	(27)
’21	(6)	(7)	(5)	(6)	(24)
’20	(7)	(6)	(5)	(5)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.36)	(0.77)	—	—	—
’25	1.39	(1.00)	(0.22)	(0.34)	(0.29)
’24	(0.40)	0.24	(2.80)	(1.56)	(4.62)
’23	(6.00)	(12.00)	(12.00)	(7.44)	(37.60)
’22	(4.00)	(6.40)	(6.00)	(3.60)	(19.20)
’21	(10.80)	(6.00)	(4.84)	(3.20)	(24.00)
’20	(24.00)	(18.00)	(9.34)	(24.40)	(72.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	426.00	480.00	246.00	62.00	42.40	78.00	22.00	22.00	7.60	2.30	Analyst estimates 2026–2028 Powerpack
	High	852.00	828.00	1,104.00	522.00	148.80	253.60	87.60	101.20	63.60	14.80
People
People	Employees	43	51	48	42	38	38	49	79	28	24
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	1.03	0.05
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	5	29	1
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.08	67.99	80.51
	EBT	(16)	(24)	(23)	(25)	(30)	(27)	(25)	(61)	(9)	(2)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(1,262.79)	(31.86)	(171.69)
	Net income	(16)	(24)	(23)	(25)	(30)	(27)	(25)	(61)	(9)	(2)
	Depreciation	0	0	1	1	1	1	1	1	4	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.99	14.49	0.29
	Earnings	(167.92)	(161.92)	(125.94)	(102.00)	(72.00)	(24.00)	(19.20)	(37.60)	(4.62)	(0.29)
	Cash flow	(155.05)	(136.98)	(133.66)	(92.89)	(55.07)	(21.33)	(20.34)	(14.08)	(21.97)	(1.96)
	Capex	(0.59)	(28.25)	(56.44)	(0.30)	0.00	(0.09)	(0.24)	(0.18)	(0.03)	(0.01)
	Free cash flow	(155.64)	(165.23)	(190.10)	(93.19)	(55.07)	(21.42)	(20.59)	(14.27)	(22.00)	(1.97)
	Book value	374.22	352.54	228.29	136.80	52.28	61.62	39.41	8.24	6.74	5.68
	Shares, m	0	0	0	0	0	1	1	2	2	4
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	0.00	0.58	9.65
	P/B	—	—	—	—	—	—	—	7.43	1.25	0.49
	EV/Sales	—	—	—	—	—	—	—	0.00	0.37	(0.47)
	EV/FCF	—	—	—	—	—	—	—	(2.84)	(0.24)	0.07
Cash, $m
Cash, $m	Operating cash flow	(15)	(21)	(24)	(23)	(23)	(24)	(26)	(23)	(44)	(8)
	Capex	0	(4)	(10)	0	—	0	0	0	0	0
	Free cash flow	(15)	(25)	(34)	(23)	(23)	(24)	(27)	(23)	(44)	(8)
Balance, $m
Balance, $m	Working capital	32	44	25	16	12	48	41	4	12	12
	Total debt	0	0	9	8	6	4	10	10	13	9
	Net debt	(35)	(49)	(21)	(19)	(17)	(53)	(41)	(33)	(6)	(12)
	Shareholders’ equity	35	53	41	33	22	68	51	13	13	23
Returns, %
Returns, %	ROA	(35.11)	(48.75)	(39.18)	(46.35)	(59.53)	(42.05)	(31.63)	(86.40)	(17.93)	(2.94)
	ROIC	0.00	(432.43)	(80.41)	(122.16)	(271.65)	(100.28)	(183.57)	0.00	(173.87)	(56.36)
	ROE	(38.34)	(55.40)	(48.75)	(68.13)	(108.36)	(60.04)	(41.96)	(189.23)	(69.11)	(6.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PHIO Phio Pharmaceuticals Corp.	$10.8M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−58.67% (below 0%: shrinking)	0.00%	0.00%	Compare
TPST Tempest Therapeutics, Inc.	$10.7M	— (loss-making)	—	−71.57% (below 0%: shrinking)	n/m	+67.04% (above 0%: growing)	0.00%	0.00%	Compare
KPRX Kiora Pharmaceuticals, Inc.	$10.7M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%	Compare
GDTC CytoMed Therapeutics Limited	$10.3M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
BLRX BioLineRx Ltd.	$10.2M	— (loss-making)	— (loss-making)	−3.29% (below 0%: shrinking)	n/m	−1,827.71% (below 0%: shrinking)	79.93%	(1,215.31%)
LTRN Lantern Pharma Inc.	$10.0M	— (loss-making)	—	—	n/m	+25.31% (above 0%: growing)	0.00%	0.00%	Compare
TOVX Theriva Biologics, Inc.	$9.7M	0.1×	—	+33.08% (above 0%: growing)	n/m	+34.69% (above 0%: growing)	100.00%	0.00%	Compare
BIVI BioVie Inc.	$9.6M	— (loss-making)	—	—	n/m	+26.50% (above 0%: growing)	0.00%	0.00%	Compare
LSTA Lisata Therapeutics, Inc.	$9.6M	— (loss-making)	— (loss-making)	−98.30% (below 0%: shrinking)	n/m	+33.04% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$10.1M	—	—	−71.57%	—	+29.77%	0.00%	0.00%

All 614 Biotechnology stocks →

BioLineRx Ltd. (BLRX) key facts

Concern: BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
BioLineRx Ltd. (BLRX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, BLRX traded at $2.04, a market capitalization of $10.2 million.
Return on equity was −6.38% and debt-to-equity 0.40.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −13.80 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.